Clinical Registry on Sudden Death Primary Prevention at Latin America (ESCAPE-ICD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01422174
Recruitment Status : Withdrawn (Study stopped due to lost of interest.)
First Posted : August 23, 2011
Last Update Posted : March 3, 2015
Information provided by (Responsible Party):
Biotronik SE & Co. KG

August 18, 2011
August 23, 2011
March 3, 2015
March 2012
January 2015   (Final data collection date for primary outcome measure)
Prevalence of patients with MADIT, MADIT II and MUST at Latin American countries [ Time Frame: Patients that suffered from MI in the last 3 years and during the enrollment period ]

Primary Outcome at Stage 1: Determine prevalence of patients with myocardial infarction and high risk of sudden death at Latin America, that fulfill inclusion criteria

Primary Outcome at Stage 2: Compare MACE development in patients that receive ICD implantation vs patients that receive other type of treatment (non ICD)

Same as current
Complete list of historical versions of study NCT01422174 on Archive Site
Study incidence of Arrhythmic mortality and serious arrhythmic events, evaluated through remote monitoring [ Time Frame: 5 years (until end 2018) ]
Same as current
Not Provided
Not Provided
Clinical Registry on Sudden Death Primary Prevention at Latin America
Clinical Registry on Sudden Death Primary Prevention at Latin America (rEgiStro Clinico en America Latina de Prevencion Primaria en muErte Subita)

INTRODUCTION: Sudden cardiac death is one of the most important reasons of death at industrialized countries. Despite its importance, nowadays Clinical Guidelines are not as extended as expected, with respect to indications for primary prevention defibrillator implantation, following MADIT II and MUSTT criteria, especially at Latin American countries.

OBJECTIVES: This Project is designed with the purpose of providing tools to help spreading primary prevention by the means of clinical evidence on real risk of death in this group of patients.


  • retrospective (at stage 1); prospective (at stage 2)
  • multi-center (minimum 25-30 centres)
  • international (Argentina, Brazil, Colombia, Chile, Mexico and Venezuela)
  • non randomized.
  • Sample size: at screening about 12.500 patients and 962 patients at treatment stage

REGISTRY DEVICES: CE marked (Conformité Européenne) single-chamber, dual-chamber or CRT (Cardiac Resynchronization Therapy) implantable cardiac defibrillator (ICD).

REGISTRY STAGES 2 stages will be performed:

  • Stage 1 (Screening): 12500 patients with MI and LVEF<40% will be evaluated, to know ICD implantation prevalence in such patients at Latin American countries
  • Stage 2 (Treatment): after patient screening and as per clinical decision, 962 patients will be entered in group 1 and 2 (481 each, 1:1)


  • Dr. Sergio Dubner. Clinica y Maternidad Suizo Argentina and De Los Arcos Sanatorio. Buenos Aires - Argentina
  • Dr. William Uribe. CES CARDIOLOGIA. Medellin - Colombia


• Dr Francisco Javier Alzueta Rodriguez. Hospital Clinico Universitario Virgen de la Victoria. Malaga - Spain


  • Patient enrollment period initiation: September 2011
  • End of patient enrollment: September 2013
  • End of FUs: September 2018
  • Registry closure and data analyses: 4Q 2018.

REGULATORY CONSIDERATIONS As this is an observational registry, no submission to National Authorities is required.

Observational Model: Cohort
Not Provided
Not Provided
Non-Probability Sample
Patients at Latin American countries that fulfill MADIT, MADIT II and/or MUSTT criteria.
  • Myocardial Infarction
  • Sudden Death
Procedure: Implantable Cardio Defibrillator (ICD),
Standard ICD implantation (as per clinical decision)
Other Name: CE approved devices
  • ICD implantation
    Patients that receive an ICD implantation (non randomized, by clinical decision) will enter this group
    Intervention: Procedure: Implantable Cardio Defibrillator (ICD),
  • Non ICD implantation
    Patients that do not receive ICD implantation (non randomized, by clinical decision); they can receive any other treatment (e.g. antiarrhythmic drugs)
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2015
January 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients that had Acute Myocardial Infarction (>40 days post-AMI) documented with the presence of Q-wave or cardiac-specific enzymatic markers of myocardial necrosis (CK-MB/troponin), occurred within 3 years previous to enrollment / after June 2008.
  • Left Ventricular Ejection Fraction (LVEF) ≤40% post-revascularization (if no revascularization, measurement performed <3 months previous to patient enrollment, >40 days post-AMI and >3 months post-revascularization -if applicable-).

Exclusion Criteria:

  • Patient with an implanted ICD
  • <18 years old
  • Pregnant or breast feeding women
  • Patients that are already participating in other Investigational Study or Registry
  • Non signed patient informed consent or refusal from patient's reference physician to patient participation
  • Patient inability to comply with protocol (assist to scheduled follow-ups), due to: residence displacement out of center's activity area; unstable geographical situation or at very long distance from the center; unstable medical and/or psychological condition
  • Cardiac transplanted (or in transplant waiting list)
  • Severe Heart Failure (or other co-morbidity: cancer, renal failure, etc.)
  • Life expectancy lower than 1 year
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Biotronik SE & Co. KG
Biotronik SE & Co. KG
Not Provided
Principal Investigator: Sergio J Dubner, MD, FACC Clínica y Maternidad Suizo Argentina and De Los Arcos Sanatorio. Buenos Aires, Argentina
Principal Investigator: William Uribe, MD CES Cardiología. Medellin, Colombia
Study Chair: Francisco J Alzueta Rodriguez (Study Clinical Advisor), Dr Hospital Clínico Universitario Virgen de la Victoria. Málaga, Spain
Biotronik SE & Co. KG
March 2015